Article

Predictors and risk factors for PsA transition in patients with psoriasis


 

Key clinical point: Patients with psoriasis who experienced nail pitting, musculoskeletal symptoms, or inflammation or had high body mass index (BMI) were at a higher risk of developing psoriatic arthritis (PsA).

Major finding: Patients with psoriasis who had arthralgia (pooled risk ratio [pRR] 2.15; 95% CI 1.16-3.99) or imaging-detected musculoskeletal inflammation or structural damage (pRR 3.72; 95% CI 2.12-6.51) were at a significantly higher risk for PsA. Other predictors of PsA included nail pitting (pooled hazard ratio [HR] 2.14; 95% CI 1.32-3.46) and higher BMI (adjusted HR 1.17; 95% CI 1.04-1.31).

Study details: Findings are from a meta-analysis of 16 cohort studies and 10 case-control studies including patients with skin/nail psoriasis without a diagnosis of PsA.

Disclosures: This study was partially funded by Novartis Farma, Italy. The authors declared no conflict of interests.

Source: Zabotti A et al. Rheumatol Ther. 2021 Oct 10. doi: 10.1007/s40744-021-00378-w.

Recommended Reading

U.S. arthritis prevalence continues steady rise; activity limitations grow more rapidly
Psoriatic Arthritis ICYMI
Tramadol linked to higher risk of mortality, compared with codeine
Psoriatic Arthritis ICYMI
Better COVID-19 outcomes confirmed in TNF inhibitor users
Psoriatic Arthritis ICYMI
Disease activity-guided dose optimization of TNF inhibitors safe and effective in PsA
Psoriatic Arthritis ICYMI
Psoriasis patients initiating biologics more likely to develop PsA
Psoriatic Arthritis ICYMI
PsA: Phase 3 confirms rapid and significant response of secukinumab on synovitis
Psoriatic Arthritis ICYMI
Study identifies different patient priorities when selecting biologics for PsA
Psoriatic Arthritis ICYMI
Psoriasis patients with more severe disease at higher risk of developing PsA
Psoriatic Arthritis ICYMI
PsA: Long-term apremilast offers clinical benefits in ACR20 nonresponders
Psoriatic Arthritis ICYMI
Itch relief major contributor for tofacitinib-mediated–improved QoL in PsA
Psoriatic Arthritis ICYMI